- Conditions
- Chronic Kidney Disease
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 119
- States / cities
- Huntsville, Alabama • Montgomery, Alabama • Sheffield, Alabama + 106 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 33
- States / cities
- Sun City, Arizona • Surprise, Arizona • Concord, California + 29 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 120
- States / cities
- Fairhope, Alabama • Anchorage, Alaska • Gilbert, Arizona + 105 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more
- Conditions
- Weight Management
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 53 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 17
- States / cities
- Little Rock, Arkansas • Sacramento, California • Aurora, Colorado + 14 more
- Conditions
- Healthy Participants
- Interventions
- Elecoglipron, Atorvastatin, Rosuvastatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Healthy Participants
- Interventions
- Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Glendale, California • Brooklyn, Maryland
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Elecoglipron, Semaglutide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 57 more